Understanding gene expression in prostate cancer to identify aggressive forms
Official title: Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer
Funded at Brigham and Women's Hospital · NIH-10818538 · Data updated 2026-11-12
This study is looking at how certain genes in the supportive tissue of the prostate can help doctors tell the difference between aggressive and less aggressive prostate cancer, so they can better decide who needs treatment right away and who can safely wait and watch.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $439,959 |
| NIH project number | 5R37CA227190-07 |
| Project ID | NIH-10818538 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with prostate cancer who are at varying risk levels for disease progression.
✕Less likely to help
Patients with non-cancerous prostate conditions or those who have already undergone extensive treatment for prostate cancer may not benefit from this research.
What this research studies
This research investigates how gene expression in the prostate's supportive tissue, known as the stroma, can help distinguish between aggressive and non-aggressive forms of prostate cancer. By analyzing tissue samples from patients, the study aims to identify molecular biomarkers that can predict which patients may require immediate treatment versus those who can safely opt for active surveillance. The approach includes advanced techniques like laser-capture microdissection to isolate specific cell types and assess their gene expression patterns. This could lead to more personalized treatment strategies for prostate cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools that help patients avoid unnecessary treatments and focus on more effective management of their prostate cancer.
How similar studies have gone: Previous research has shown promise in identifying biomarkers for prostate cancer aggressiveness, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Birmann, Brenda M — Brigham and Women's Hospital
- Study coordinator: Birmann, Brenda M
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.